Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | ShortHER study: validating the AJCC prognostic stage in HER2+ breast cancer

Maria Vittoria Dieci • 14 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Trastuzumab
ShortHER

Maria Vittoria Dieci, MD, of the University of Padua, Padova, Italy, describes the results of the ShortHER study (NCT00629278) which aimed to validate the introduction of prognostic staging in the American Joint Committee on Cancer (AJCC) guidelines. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Maria Vittoria Dieci

5:54
ROXANE: impact of 21-gene assay on treatment for early breast cancer
Maria Vittoria Dieci • 22 May 2020
10:07
Importance of biomarkers when evaluating heterogeneity in HER2+ metastatic BC
Maria Vittoria Dieci • 26 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals